Bluesky briefly suspended JD Vance's account after he joined
In Brief
When U.S. Vice President JD Vance joined Bluesky on Wednesday evening, he got banned immediately. However, his account was restored after a while, with Bluesky saying that the ban was issued after the social network's system that looks for impersonating attempts fired a warning.
'Vice President Vance's account was briefly flagged by our automated systems that try to detect impersonation attempts, which have targeted public figures like him in the past. The account was quickly restored and verified so people can easily confirm its authenticity,' A Bluesky spokesperson told TechCrunch in a statement.
'We welcome the Vice President to join the conversation on Bluesky,' the spokesperson said.
Vance's first post on Bluesky was about the Supreme Court's decision to uphold a Tennessee law that bars gender-affirming care for transgender minors.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Don't regulate us like radio, music streamer Spotify tells CRTC
OTTAWA — Music streamer Spotify says Canada's federal broadcast regulator shouldn't impose rules meant for radio on streaming services. Appearing before a CRTC hearing today, company representatives compared regulating Spotify like a radio station to treating Uber like a horse and buggy. In its written submission, Spotify argued the CRTC doesn't have the jurisdiction to extend rules governing commercial negotiations and disputes in the broadcast sector to online players. The CRTC is holding a hearing on market dynamics as part of its work to implement the Online Streaming Act, which updated broadcasting laws to capture online platforms. During previous hearings, large cable and broadcasting companies like Bell and Rogers called on the CRTC to loosen existing rules for traditional players. They're taking aim at regulations governing how cable channels must be packaged and disputes about carriage of cable channels. This report by The Canadian Press was first published June 20, 2025. Anja Karadeglija, The Canadian Press
Yahoo
39 minutes ago
- Yahoo
Eli Lilly (NYSE:LLY) Faces $7 Billion Lawsuit While Partnering With Innovative Biotech
Eli Lilly has been in the spotlight recently with a 3.96% share price increase over the past month. The selection of RyboDyn Inc. to join Lilly Gateway Labs stands out among recent developments, signaling strengthened research capabilities in precision immunotherapies and potentially bolstering investor confidence. Additionally, the company's legal entanglement with the lawsuit concerning Actos, following a class certification affirmation, highlights ongoing challenges in the pharmaceutical sector. The company's ongoing talks to acquire Verve Therapeutics also show its commitment to growing its gene-editing capabilities. These events have added weight to the broader market's trends. We've identified 2 warning signs for Eli Lilly (1 can't be ignored) that you should be aware of. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Recent developments at Eli Lilly, such as the RyboDyn Inc. collaboration, have potential implications for its strategic growth, particularly in precision immunotherapies. This aligns with the company's narrative of expanding capabilities in oncology and immunology, indicating possible enhancements in revenue and earnings forecasts over the long term. Additionally, as Eli Lilly progresses with Phase III trials, including those for orforglipron, the anticipated product approvals could bolster revenue avenues by tapping into high-demand markets like diabetes and obesity treatments. Over the past five years, Eli Lilly's total shareholder return was a very large 430.14%, demonstrating substantial long-term growth despite recent underperformance against the US Pharmaceuticals industry, which saw a 8.9% drop over the past year. This impressive five-year return provides context to the company's current position, underscoring a history of robust shareholder value creation. Given the ongoing acquisition talks with Verve Therapeutics and Eli Lilly's significant investment in both manufacturing and R&D, the outlook for future revenue and earnings remains optimistic. However, potential regulatory hurdles and pricing pressures, particularly in the U.S. market, highlight possible challenges. The shares, with a current price of US$775.12, are 21.0% below the analyst consensus target of US$981.63. This discount suggests room for growth, should the company meet or exceed the analyst expectations on revenue and earnings. Learn about Eli Lilly's future growth trajectory here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:LLY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
39 minutes ago
- Yahoo
Mahmoud Khalil ordered released by federal judge
A federal judge is ordering the release of Columbia University pro-Palestinian activist Mahmoud Khalil. U.S. District Judge Michael Farbiarz indicated that he will issue an order requiring that Khalil be released today. He denied a motion by the government to stay the ruling for seven days. MORE: Judge denies Palestinian activist Mahmoud Khalil's request for release The judge asked the parties to consult with a magistrate judge about any conditions that will be attached to Khalil's release on bail. Last week, Judge Farbiarz issued a preliminary injunction barring the Trump administration from continuing to detain Khalil based on Secretary of State Marco Rubio's determination that his continued presence in the country would pose a risk to foreign policy -- but the judge subsequently sided with the government in ruling that Khalil could continue to be detained on the grounds that he misrepresented information on his green card application. Khalil, a green card holder who is married to an American citizen, has been held in a detention facility since he was arrested by ICE agents in New York City in March. This is a developing story. Please check back for updates.
